Exomind vs Ketamine Treatment for Depression

Ketamine and esketamine are newer, rapid-acting treatments for treatment-resistant depression, offering a different profile of benefits and considerations compared to rTMS.

Ketamine and esketamine can produce rapid improvement in mood, sometimes within hours to days, making them particularly valuable in situations requiring faster relief. rTMS typically produces improvement more gradually, over two to four weeks of a structured treatment course.

Ketamine is administered via intravenous infusion or, in the case of esketamine, intranasal spray, under medical supervision due to its dissociative and sedating effects during administration. rTMS is delivered via a magnetic coil applied to the scalp, with the patient remaining fully alert throughout, and no dissociative effects.

Ketamine carries a risk of dissociative effects, elevated blood pressure during administration, and, given its properties, a recognised potential for misuse, requiring careful monitoring. rTMS's side effects are largely localised to the scalp (discomfort, headache) without these systemic or dissociative effects.

Ketamine may be preferred when rapid symptom relief is a priority, such as with significant suicidal ideation requiring urgent intervention, while rTMS may be preferred for patients seeking a treatment without dissociative effects or misuse potential, and who can accommodate a longer treatment course.

Dr. Muhammad Shoaib Zafar helps patients understand the distinct roles of rTMS and ketamine-based treatments in managing treatment-resistant depression.

This page is provided for general educational purposes and does not replace an individual psychiatric assessment.